{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for dimethyl root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT02675452: Phase 1 Interventional Completed Relapsed or Refractory Multiple Myeloma
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02892422: Phase 3 Interventional Completed Schizophrenia
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02112695: Not Applicable Interventional Completed Sports Nutritional Sciences
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Tematropium, a muscarinic acetylcholine receptor antagonist that was studied as an antiasthmatic agent. Information about the current use of this compound is not available.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
JAN:PROFLUTHRIN [JAN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
JAN:EZ-EMPENTHRIN [JAN]
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Investigational
Source:
NCT00229437: Phase 2 Interventional Completed Diabetic Neuropathies
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
USAN:SCOPAFUNGIN [USAN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Scopafungin (also known as GE4800) is an inhibitor of oxidative phosphorylation in mitochondria. Scopafungin also inhibits, in vitro, a variety of pathogenic fungi, yeasts, and gram-positive bacteria.
Status:
Investigational
Source:
NCT02332720: Phase 2 Interventional Completed Hepatitis C
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ruzasvir (previously known as MK-8408) was developed as a nonstructural protein 5A (NS5A) inhibitor for the treatment of hepatitis C and hepatitis C infection. Ruzasvir successfully completed phase II clinical trial for combination therapy. The obtained results have shown that ruzasvir in combination with uprifosbuvir was highly effective and well-tolerated in participants infected with hepatitis C virus genotypes GT1, GT2, GT4, GT5, and GT6, with a lower efficacy in GT3-infected persons.
